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Background
In patients undergoing mechanical ventilation for Acute 
Respiratory Distress Syndrome (ARDS), neuromuscular 
blocking agents (NMBAs) may improve oxygenation and 
decrease ventilator-induced lung injury but may also 
cause muscle weakness.
Methods
Objective: To identify if 48 hour therapy with the NMBA 
cisatracurium early in the course of ARDS reduces 
adjusted 90-day in-hospital mortality rate.
Design: Multicenter, double blind, randomized clinical 
trial.
Setting: Twenty multidisciplinary intensive care units in 
France
Subjects: Patients presenting with onset of severe ARDS 
within the previous 48 hours. Severe ARDS was deﬁ ned 
as a ratio of the partial pressure of arterial oxygen to the 
fraction of inspired oxygen of less than 150, with a 
positive end-expiratory pressure of 5 cm or more of water 
and a tidal volume of 6 to 8 ml per kilogram of predicted 
body weight.
Intervention: After enrollment, 340 patients were ran dom-
ized to receive either cisatracurium besylate (n = 178) or 
placebo (n = 162). All patients were sedated to a Ramsay 
sedation score of 6 using sulfentanil and midazolam prior 
to intervention. A dose of 15 mg cisatracurium besylate 
or placebo was then administered, followed by a con-
tinuous infusion of 37.5  mg/hour for 48  hours. Patients 
were not monitored for depth of paralysis.
Outcomes: Th e primary outcome was the proportion of 
patients who died either before hospital discharge or 
within 90 days after study enrollment (i.e., the 90-day in-
hospital mortality rate), adjusted for predeﬁ ned 
covariates and baseline diﬀ erences between groups with 
the use of a Cox model.
Results
Th e crude 90-day mortality was 31.6% (95% conﬁ dence 
interval [CI], 25.2 to 38.8) in the cisatracurium group and 
40.7% (95% CI, 33.5 to 48.4) in the placebo group 
(P  =  0.08). Th e hazard ratio for death at 90 days in the 
cisatracurium group, as compared with the placebo 
group, was 0.68 (95% CI, 0.48 to 0.98; P  =  0.04), after 
adjustment for the baseline PaO2:FIO2 ratio, plateau 
pressure and the Simpliﬁ ed Acute Physiology II score. 
Mortality at 28 days was 23.7% (95% CI, 18.1 to 30.5) with 
cisatracurium and 33.3% (95% CI, 26.5 to 40.9) with 
placebo (P = 0.05). Th e rate of ICU-acquired paresis did 
not diﬀ er signiﬁ cantly between the two groups.
Conclusions
In patients with severe ARDS, early administration of a 
neuromuscular blocking agent improved the adjusted 
90-day survival and increased the time oﬀ  the ventilator 
without increasing muscle weakness.
Trial Registration
NCT00299650
Commentary
Th e incidence of ARDS varies between 13.5 to 58.7 cases 
per 100,000 person years [1], and aﬀ ects 10% to 15% of all 
patients admitted to the intensive care unit [2,3]. Despite 
various treatment options, such as high positive end-
expiratory pressure, corticosteroids, recruitment 
maneuvers, conservative ﬂ uid management, and rescue © 2010 BioMed Central Ltd
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maneuvers, including prone ventilation, nitric oxide, and 
high frequency oscillation ventilation, severe ARDS has a 
mortality ranging from 40% to 60% [2,3]. Only low tidal 
volume ventilation and extracorporeal membrane 
oxygena tion have been shown to decrease mortality in 
patients with ARDS [4,5].
Neuromuscular blocking agents are currently used as a 
salvage maneuver in patients with severe ARDS in whom 
oxygenation is a challenge. Use of NMBAs has been 
hypothesized to achieve better synchronization with the 
ventilator resulting in decreased ventilator-induced lung 
injury, and improve oxygenation due to lower oxygen 
consumption [6]. NMBAs are also thought to have an 
anti-inﬂ ammatory eﬀ ect, including attenuation of inter-
leukin-6 and 8 expression [6]. However, NMBAs preclude 
the ability to monitor neurological signs clinically and 
prolonged use has been associated with increased risk of 
critical illness polyneuropathy [7], and posttraumatic 
stress disorder symptoms when compared to patients 
managed with sedatives alone [8]. Th erefore, the current 
standard of practice in the intensive care unit is to 
minimize the use of sedation, wake patients early, and 
avoid use of paralytic medications. Indeed, the Society of 
Critical Care Medicine guidelines recommend that 
NMBAs should only be used to manage ventilation and 
decrease oxygen consumption when all other means have 
been tried without success (Grade C recommendation) 
[9].
Papazian and colleagues challenge this existing 
paradigm and ask a very intriguing question whether 
short term use of NMBAs is likely to improve outcomes 
from ARDS. Th e authors in an earlier smaller study found 
that early and short course of NMBA use were associated 
with a trend toward lower 28-day mortality [10]. In the 
current study the authors found that in patients with 
severe ARDS, early administration of cisatracurium 
improved the adjusted 90-day survival and increased the 
time oﬀ  the ventilator without increasing muscle weak-
ness. Strengths of the trial include a well-deﬁ ned study 
protocol, multicenter design and early assignment to 
treatment groups, intention-to-treat analysis, and 
complete follow-up.
However, there are several important limitations that 
deserve consideration. First, although the healthcare 
providers were blinded to the best possible extent, 
complete blinding would not be possible as physicians 
can easily identify a paralyzed patient (by a thorough 
clinical exam). Th is could have introduced a systematic 
bias in the intervention arm that could have inﬂ uenced 
the outcomes. Second, it is important to note that the 
authors used hospital mortality censored at 90 days as a 
primary outcome measure. However, the abstract as well 
as the remainder of the manuscript alludes to “90-day” 
mortality rate as a primary outcome. Th e distinction is 
important because “90-day mortality” (i.e., assessing 
whether a patient is alive or dead at 90 days following 
randomization irrespective of their location) is a more 
robust outcome measure than hospital mortality cen-
sored at 90 days (i.e., assessing mortality only during 
hospital stay within the ﬁ rst 90 days of randomization) as 
the latter does not account for patients who might have 
died following hospital discharge within the ﬁ rst 90 days. 
Using in-hospital mortality rates can also make it diﬃ  cult 
to interpret outcome diﬀ erences across institutions if the 
Figure 1. Forest plot of trials comparing cisatracurium with placebo for 28-day mortality in severe ARDS. Data from studies demonstrate 
the relative risk (RR) with 95% confi dence intervals (CI) for mortality with cisatracurium vs. placebo in patients with ARDS. The RRs < 1 suggest 
reduced mortality with cisatracurium compared to placebo, whereas RRs >1 suggest increased mortality with cisatracurium. The size of the data 
markers corresponds to the weight of the studies. Larger markers imply less uncertainty from the results of the individual study and carry more 
weight in calculating the fi xed eff ects pooled estimate from the systematic review.
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discharge policies of these institutions vary. For example, 
transfer of ICU patients to long term acute care facilities, 
or earlier hospital discharges, may cause a decrease in the 
hospital mortality rate.
Th ird, although the authors noted a low risk of baro-
trauma and organ failure with NMBA use, data related to 
mechanistic pathways (e.g., decrease in biomarkers) that 
could have mediated beneﬁ cial outcome is lacking. 
Fourth, as stated by the authors the study was under-
powered to detect diﬀ erences in crude mortality rates 
and statistical signiﬁ cance was reached only after 
adjustment for baseline covariates. Finally, the authors 
used the Medical Research Council scale to evaluate 
muscle weakness at 28 days, which may be too brief to 
recognize muscle weakness especially among patients 
who require prolonged mechanical ventilation. Assessing 
long term neuromuscular weakness related to NMBA use 
[11], is likely to provide more robust safety data related to 
NMBA use.
Th is trial challenges current prevailing practice 
paradigms of whether a minimalistic approach in the 
treatment of ARDS, such as use of lighter sedation and 
no paralytic agents, improves outcomes. Nevertheless, 
this is the second study showing that short course NMBA 
may improve outcome among patients with severe ARDS 
[10,12]. We conducted an analysis from the two studies 
by pooling crude estimates of treatment eﬀ ects of NMBA 
on 28-day mortality [10,12] (Figure 1). We found that the 
use of NMBA cisatracurium lowered mortality rate 
(Relative Risk  = 0.7, 95% CI, 0.53-0.92, P  =  0.01) 
compared to placebo. However, the caveat should be 
noted that the 28-day mortality is a suboptimal outcome 
measure for assessing interventions in ARDS [13].
Recommendation
Papazian and colleagues should be commended for 
showing that early and short term administration of 
NMBAs is safe, may improve mortality, decrease duration 
of mechanical ventilation, and complications related to 
barotrauma. Th e absence of signiﬁ cant short term 
adverse eﬀ ects and the potential to improve mortality, 
although needs to be replicated in future studies, suggest 
that early and short course of NMBAs may be beneﬁ cial 
in severe ARDS.
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